1Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada
2Pharmacy Department Cross Cancer Institute, Edmonton, Alberta
3South Blvd Pharmacy, Edmonton, Alberta
4Faculty of Law, University of Alberta, Edmonton, Alberta.
Address correspondence to: Nese Yuksel, BScPharm, PharmD, FCSHP, NCMP, Faculty of Pharmacy and Pharmaceutical Sciences, 3-171 Edmonton Clinic Health Academy (ECHA), University of Alberta, Edmonton, AB, Canada T6G 1C9. E-mail: [email protected]
Received 12 January, 2017
Revised 8 March, 2017
Accepted 8 March, 2017
Previous presentation: An abstract of the results was presented at the North American Menopause Society (NAMS) 25th Annual Meeting, Washington, DC. October 2014 Menopause 2014;21(12):1329 (S10).
Funding/support: None reported.
Financial disclosure/conflicts of interest: N.Y. has provided continuing education and/or participated in Advisory Boards/Consult Meetings for Aspen Pharmaceuticals, Teva, and Pfizer, Canada.
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Website (www.menopause.org).